产品
编 号：F045183
分子式：C22H20N4O3
分子量：388.42
分子式：C22H20N4O3
分子量：388.42
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
结构图
CAS No: 1144504-35-7
产品详情
生物活性：
PQCA is a highly selective and potent muscarinic M1 receptor positive allosteric modulator. PQCA has an EC50 value of 49 nM and 135 nM on rhesus and human M1 receptor, respectively. PQCA is inactive for other muscarinic receptors. PQCA has potential to reduce the cognitive deficits associated with Alzheimer's disease.
体内研究：
PQCA (3-30 mg/kg; oral administration; single- or pair-housed male rhesus monkeys) treatment attenuates the scopolamine deficits in PAL and CPT tasks. Blockade of muscarinic signaling by scopolamine produces significant impairments in both tasks.Animal Model:Ten single- or pair-housed male rhesus monkeys (6-10 years old; 5.2-10.5 kg) with scopolamine
Dosage:3 mg/kg, 10 mg/kg, or 30 mg/kg
Administration:Oral administration
Result:Attenuated the scopolamine deficits in paired-associates learning (PAL) and the continuous-performance task (CPT).
PQCA is a highly selective and potent muscarinic M1 receptor positive allosteric modulator. PQCA has an EC50 value of 49 nM and 135 nM on rhesus and human M1 receptor, respectively. PQCA is inactive for other muscarinic receptors. PQCA has potential to reduce the cognitive deficits associated with Alzheimer's disease.
体内研究：
PQCA (3-30 mg/kg; oral administration; single- or pair-housed male rhesus monkeys) treatment attenuates the scopolamine deficits in PAL and CPT tasks. Blockade of muscarinic signaling by scopolamine produces significant impairments in both tasks.Animal Model:Ten single- or pair-housed male rhesus monkeys (6-10 years old; 5.2-10.5 kg) with scopolamine
Dosage:3 mg/kg, 10 mg/kg, or 30 mg/kg
Administration:Oral administration
Result:Attenuated the scopolamine deficits in paired-associates learning (PAL) and the continuous-performance task (CPT).
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备